Harbor Advisory Corp MA Sells 80 Shares of Johnson & Johnson (NYSE:JNJ)

Harbor Advisory Corp MA trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 0.2% during the fourth quarter, Holdings Channel reports. The fund owned 36,076 shares of the company’s stock after selling 80 shares during the quarter. Johnson & Johnson accounts for 1.7% of Harbor Advisory Corp MA’s holdings, making the stock its 22nd largest position. Harbor Advisory Corp MA’s holdings in Johnson & Johnson were worth $5,217,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. AMF Tjanstepension AB increased its position in Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after buying an additional 52,997 shares during the period. Alpha Financial Partners LLC bought a new position in Johnson & Johnson in the 3rd quarter worth approximately $209,000. Wealth Group Ltd. bought a new position in Johnson & Johnson in the 3rd quarter worth approximately $213,000. Wedge Capital Management L L P NC increased its position in Johnson & Johnson by 2.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock worth $655,000 after buying an additional 86 shares during the period. Finally, Creative Planning increased its position in Johnson & Johnson by 4.3% in the 3rd quarter. Creative Planning now owns 988,403 shares of the company’s stock worth $160,181,000 after buying an additional 41,082 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Bank of America decreased their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Leerink Partners decreased their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus decreased their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Trading Down 0.7 %

JNJ stock opened at $156.20 on Friday. The company has a market cap of $376.08 billion, a P/E ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The business has a fifty day moving average of $147.73 and a 200-day moving average of $156.01.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.29 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.